# US 2017/0362220 A1 · Novel tricyclic compounds as inhibitors of mutant idh enzymes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0362220 A1
- Document ID: US20170362220A1
- Status: Published application
- Kind: A1
- Application number: 15/532,552
- Filed: 2015-12-01
- Published: 2017-12-21
- Earliest claimed: 2014-12-05
- Assignees: Merck Sharp & Dohme Corp.
- Applicants: Merck Sharp & Dohme Corp.
- Inventors: Christian Fischer; Stephane L. Bogen; Matthew L. Childers; Francesc Xavier Fradera Llinas; Michael J. Ellis; Sara Esposite; Dawn M. Hoffman; Chunhui Huang; Solomon D. Kattar; Alexander J. Kim; John W. Lampe; Michelle R. Machacek; Daniel R. McMasters; Dann L. Parker, Jr.; Michael H. Reutershan; Nunzio Sciammetta; Patrick Pengcheng Shao; David L. Sloman; Wanying Sun; Feroze Ujjainwalla; Zhicai Wu; Yang Yu; Craig R. Gibeau
- Web page: https://patentgrep.com/patent/US20170362220A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 35/00: Antineoplastic agents
- C07D 471/14: Ortho-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes (I); wherein A is —C(R1)═ or —N═; and X is selected from the group consisting of: (II-i), and (II-ii). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.

## Claims

### Claim 1

A compound of formula (I):
wherein A is —C(R1)═ or —N═, and R1 is hydrogen or hydroxyl;
X is selected from the group consisting of:
B is —C(R9)(R10)—, —N(R10)—, —O—, —S— or —S(O)2—;
D is —C(R4)(R5)—, —N(R5)—, —O— or —S—;
m is 0 or 1; n is 0 or 1; p is 0 or 1; q is 0 or 1;
the E ring is a C3-6carbocyclic ring or a 3-6 membered saturated, partially unsaturated or aromatic heterocyclic ring containing 1-2 heteroatoms independently selected from O, S and N;
the E ring is optionally substituted with one to four substituents independently selected from Rb;
and optionally, the E ring is further fused to another 4-6 membered carbocyclic ring;
R is selected from the group consisting of:
(1) halogen,
(2) —CN, and
(3) —(C═O)t—Ra, wherein t is 0 or 1;
R2 and R3 together form an oxo; or alternatively, each occurrence of R2 and R3 is independently selected from the group consisting of:
(1) hydrogen,
(2) C1-6alkyl, and
(3) —O—C1-6alkyl;
each occurrence of R4, R6, R7, R9, R11 and R12 is independently selected from the group consisting of:
(1) halogen,
(2) —CN, and
(3) —(C═O)t—Ra, wherein t is 0 or 1;
each occurrence of R5 and R10 is independently selected from the group consisting of:
(1) hydrogen, and
(2) C1-6alkyl;
R8 is selected from the group consisting of:
(1) hydrogen,
(2) —CN, and
(3) C1-6alkyl;
each occurrence of Ra is independently selected from the group consisting of:
(1) hydrogen,
(2) —(O)t—Rd, wherein t is 0 or 1; Rd is selected from the group consisting of (a) hydrogen, (b) C1-6alkyl, (c) C3-7cycloalkyl, and (d) phenyl;
wherein each of the C1-6alkyl of (b) and C3-7cycloalkyl of (c) is optionally substituted with one to four substituents independently selected from Rb,
(3) —NRxRy, wherein each of Rx and Ry is independently selected from the group consisting of (a) hydrogen, (b) C1-6alkyl, (c) C3-6cycloalkyl, (d) —O—C1-6alkyl, (e) phenyl optionally substituted with one to four halogens, and (f) heterocyclyl;
wherein the C1-6alkyl of (b) is optionally substituted with one to four substituents independently selected from halogen, —O—C1-4alkyl, C3-6cycloalkyl, and heterocyclyl; and
the C3-6cycloalkyl of (c) is optionally substituted with one to four substituents independently selected from halogen, —O—C1-4alkyl, C3-6cycloalkyl, heterocyclyl, and C1-4alkyl, which is optionally substituted with one to four halogens,
the heterocyclyl of (f) is optionally substituted with one to four substituents independently selected from halogen, C1-4alkyl, —O—C1-4alkyl, C3-6cycloalkyl, and heterocyclyl;
(4) C2-6alkenyl, optionally substituted with one to four substituents independently selected from Rb,
(5) C5-6cycloalkenyl, optionally substituted with one to four substituents independently selected from Rb,
(6) aryl, optionally substituted with one to four substituents independently selected from Rb, and
(7) heterocyclyl, optionally substituted with one to four substituents independently selected from Rb;
each occurrence of Rb is independently selected from the group consisting of:
(1) halogen,
(2) —CN,
(3) oxo,
(4) —(O)t—Rd, wherein t is 0 or 1; Rd is selected from the group consisting of (a) hydrogen, (b) C1-6alkyl, (c) C3-7cycloalkyl, and (d) heterocyclyl;
wherein the C1-6alkyl of (b) is optionally substituted with one to four substituents independently selected from (i) halogen, (ii) hydroxyl, (iii) —O—C1-6alkyl, (iv) C3-6 cycloalkyl optionally substituted with 1-3 halogens, (v) —NRxRy, wherein each of Rx and Ry is independently selected from the group consisting of hydrogen, C1-6 alkyl, C3-6cycloalkyl, phenyl optionally substituted with one to four halogens, and heterocyclyl, and (vi) heterocyclyl;
the C3-7cycloalkyl of (c) is optionally substituted with one to four substituents independently selected from (i) halogen, and (ii) C1-6alkyl, which is optionally substituted with one to four halogens, and (iii) —CN; and
the heterocyclyl of (d) is optionally substituted with one to four substituents independently selected from (i) halogen, (ii) hydroxyl, (iii) oxo, (iv) C1-6alkyl optionally substituted with one to four halogens, (v) —O—C1-6alkyl, (vi) heterocyclyl optionally substituted with halogen or hydroxyl, and (vii) —NRjRk;
wherein each of Rj and Rk is independently selected from the group consisting of hydrogen and C1-6alkyl;
(5) —(C═O)t—Rc, wherein t is 0 or 1; Rc is selected from the group consisting of hydrogen, hydroxyl, C1-6alkyl, C2-6alkenyl, —O—C1-6alkyl, —NRxRy, and heterocyclyl;
wherein each of Rx and Ry is independently selected from the group consisting of (a) hydrogen, (b) C1-6alkyl, (c) C2-6alkenyl, (d) C3-6cycloalkyl, (e) phenyl optionally substituted with one to four halogens, and (f) heterocyclyl;
wherein the C1-6alkyl of (b) is optionally substituted with one to four substituents independently selected from halogen, —O—C1-4alkyl, C3-6cycloalkyl, heterocyclyl, and —(C═O)—NRjRk, wherein each of Rj and Rk is independently hydrogen or C1-6alkyl;
the C3-6cyclolkyl of (d) is optionally substituted with one to four substituents independently selected from halogen and C1-4alkyl, which is optionally substituted with one to four halogens, and
the heterocyclyl of (f) is optionally substituted with one to four substituents independently selected from halogen, —CN, C1-6alkyl, and —O—C1-6alkyl;
(6) C2-6alkenyl; and
(7) phenyl, optionally substituted with one to four substituents independently selected from halogen, C1-6alkyl, and —O—C1-6alkyl;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1 having the following formula:
wherein A is —CH═, —C(OH)═, or —N═;
B is —CH(R9)—, —NH—, or —O—;
D is —CH(R4)—, —NH—, or —O—; and
the E ring is a C3-6carbocyclic ring or a 3-6 membered saturated, partially unsaturated or aromatic heterocyclic ring containing 1-2 heteroatoms independently selected from O, S and N; and the E ring is optionally substituted with one to four substituents independently selected from Rb;
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 2)

The compound of claim 2 selected from the group consisting of:
wherein A is —CH═, —C(OH)═, or —N═; and
R2 and R3 together form an oxo; or alternatively, each of R2 and R3 is hydrogen;
a is 0, 1 or 2; when a is 2, the two Rb substituents are attached to the same or different substitutable positions on fused ring;
or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 3)

The compound of claim 3 of the following formula:
wherein A is —CH═, —C(OH)═, or —N═;
or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

The compound of claim 1 having the following formula:
wherein A is —CH═, —C(OH)═, or —N═; and
the E ring is a C3-6carbocyclic ring or a 3-6 membered saturated, partially unsaturated or aromatic heterocyclic ring containing 1 or 2 heteroatoms independently selected from O, S and N; and the E ring is optionally substituted with one to three substituents independently selected from Rb;
or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 5)

The compound of claim 5, wherein the E ring is selected from the group consisting of:
azetidinyl,
C3-6cycloalkyl,
oxetanyl,
phenyl,
pyridinyl,
pyrrolidinyl,
tetrahydrofuranyl, and
tetrahydropyranyl;
or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 6)

The compound of claim 6 having the following formula:
wherein A is —CH═, —C(OH)═, or —N═; and
b is 0 or 1; c is 0 or 1; d is 0 or 1;
e is 0 or 1; f is 0 or 1; g is 0 or 1; h is 0 or 1;
or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 6)

The compound of claim 6, selected from the group consisting of:
wherein a is 0, 1, or 2; when a is 2, the two Rb substituents are attached to the same or different substitutable positions on spiro ring;
or a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 4)

The compound of claim 4, wherein each occurrence of R4, R6, R7, R9, R11 and R12, when present, is independently selected from the group consisting of hydrogen and C1-6alkyl optionally substituted with one to four halogens; or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 3)

The compound of claim 3, wherein R8 is hydrogen or C1-4alkyl; or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 2)

The compound of claim 2, wherein:
R is selected from the group consisting of:
(1) hydrogen,
(2) halogen,
(3) C1-6alkyl, optionally substituted with one to four substituents independently selected from (a) halogen, (b) —CN, (c) —ORd, (d) —(C═O)—Re, (e) —NRxRy, and (f) heterocyclyl; wherein Rd is hydrogen or C1-4alkyl optionally substituted with heterocyclyl;
Re is hydroxyl or heterocyclyl;
each of Rx and Ry is independently selected from the group consisting of (i) hydrogen, (ii) C1-6alkyl, which is optionally substituted with one to four substituents independently selected from halogen, —O—C1-4alkyl, C3-6cycloalkyl, and heterocyclyl, (iii) C3-6cycloalkyl, which is optionally substituted with one to four substituents independently selected from halogen, and C1-4alkyl, which is optionally substituted with one to four halogens, and (iv) heterocyclyl;
(4) —O—C1-6alkyl,
(5) —(C═O)t—NRxRy, wherein t is 0 or 1; each of Rx and R is independently selected from the group consisting of (a) hydrogen, (b) C1-6alkyl, (c) C3-6cycloalkyl, (d) phenyl optionally substituted with one to four halogens, and (e) heterocyclyl;
wherein the C1-6alkyl of (b) is optionally substituted with one to four substituents independently selected from halogen, —O—C1-4alkyl, C3-6cycloalkyl, and heterocyclyl; and
the C3-6cycloalkyl of (c) is optionally substituted with one to four substituents independently selected from halogen and C1-4alkyl optionally substituted with one to four halogens, and
(6) —(C═O)t-heterocyclyl, wherein t is 0 or 1; and the heterocyclyl is optionally substituted with one to four substituents independently selected from Rb;
or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 8)

The compound of claim 8, wherein:
R is selected from the group consisting of:
(1) hydrogen,
(2) C1-6alkyl, optionally substituted with one to four substituents independently selected from halogen, —CN, and —ORd; wherein Rd is hydrogen or C1-4alkyl optionally substituted with heterocyclyl;
(3) —NRjRk, wherein each of Rj and Rk is independently selected from the group consisting of hydrogen and C1-6alkyl; wherein the C1-6alkyl is optionally substituted with one to four halogens, and
(4) —(C═O)-heterocyclyl, wherein the heterocyclyl is optionally substituted with halogen or C1-6alkyl; and
(5) heterocyclyl, optionally substituted with one to four substituents independently selected from the group consisting of halogen, oxo, —O—C1-6alkyl, C1-6alkyl optionally substituted with one to four halogens, —NRjRk, and heterocyclyl optionally substituted with halogen or hydroxyl; wherein each of Rj and Rk is independently selected from the group consisting of hydrogen and C1-6alkyl;
wherein each occurrence of the heterocyclyl of (2), (4) and (5) is independently selected from the group consisting of azaindolyl, azetidinyl, 1,4-dioxanyl, imidazolyl, isoindolinyl, isoxazolyl, morpholinyl, oxazolidinyl, piperidinyl, pyridinyl, pyrazolyl, pyrrolidinyl, tetrahydropyranyl, and thiazolyl;
or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 3)

The compound of claim 3, wherein:
each occurrence of Rb is independently selected from the group consisting of:
(1) halogen,
(2) hydroxyl,
(3) —CN,
(4) oxo,
(5) —O—C1-6alkyl,
(6) —(C═O)—Rc, wherein Rc is selected from the group consisting of hydrogen, hydroxyl, C1-6alkyl, —O—C1-6alkyl, —NRjRk, and heterocyclyl; wherein the heterocyclyl is optionally substituted with one to four substituents independently selected from halogen and C1-6alkyl; and each of Rj and Rk is independently selected from the group consisting of hydrogen and C1-6alkyl,
(7) C1-6alkyl, optionally substituted with one to four halogens,
(8) phenyl, optionally substituted with one to four halogens, and
(9) heterocyclyl, optionally substituted with one to four substituents independently selected from halogen, oxo, C1-6alkyl optionally substituted with one to four halogens, —O—C1-6alkyl, heterocyclyl optionally substituted with halogen or hydroxyl, and —NRjRk; wherein each of Rj and Rk is independently selected from the group consisting of hydrogen and C1-6alkyl;
or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 8)

The compound of claim 8, wherein:
each occurrence of Rb is independently selected from the group consisting of:
(1) halogen,
(2) hydroxyl,
(3) oxo,
(4) —O—C1-6alkyl,
(5) —(C═O)—Rc, wherein Rc is selected from the group consisting of hydrogen, hydroxyl, and C1-6alkyl, and
(6) C1-6alkyl, optionally substituted with one to four halogens;
or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 3)

The compound of claim 3,
wherein:
each occurrence of the heterocyclyl of R and Rb is independently selected from the group consisting of:
8-azabicyclo[3.2.1]octanyl, 2-azaspiro[3.3]heptanyl, azaindolyl, azetidinyl, 2,5-diazabicyclo[2.2.2]octanyl, 1,6-diazaspiro[3.3]heptanyl, 2,6-diazaspiro[3.3]heptanyl, 2,3-dihydro-1,4-dioxinyl, 3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazinyl, 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazolyl, 1,4-dioxanyl, hexahydro-1H-furo[3,4-c]pyrrolyl, 1,2,4,5,6,6a-hexahydropyrrolo[3,4-b]pyrrolyl, imidazolyl, 1H-imidazo[4,5-b]pyridinyl, isoindolinyl, isoxazolyl, morpholinyl, octahydrocyclopenta[1,4]oxazinyl, octahydro-1H-imidazo[4,5-c]pyridinyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, 3-oxa-6-azabicyclo[3.2.0]heptanyl, 6-oxa-3-azabicyclo[3.1.1]heptanyl, 2-oxa-5-azabicyclo[2.2.2]octanyl, 3-oxa-8-azabicyclo[3.2.1]octanyl, 8-oxa-3-azabicyclo[3.2.1]octanyl, 1-oxa-8-azaspiro[4.5]decanyl, 2-oxa-6-azaspiro[3.3]heptanyl, 4-oxa-7-azaspiro[2.5]octanyl, 6-oxa-2-azaspiro[3.4]octanyl, 7-oxa-2,5-diazaspiro[3.4]octanyl, 3-oxa-1,7-diazaspiro[4.4]nonanyl, 1,4-oxazepanyl, oxazolidinyl, oxetanyl, piperazinyl, piperidinyl, pyrazolo[1,5-b]pyridazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolidinyl, pyrrolyl, tetrahydrofuranyl, 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazinyl, tetrahydropyranyl, 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazinyl, 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridinyl, 1,2,3,6-tetrahydropyridinyl, 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazinyl, 4,5,6,7-tetrahydro-[1,2,3]triazolo[1,5-a]pyrazinyl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyrazinyl, thiazolyl, and thiophenyl;
or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 1)

The compound of claim 1 selected from the group consisting of:
6-{[(3r,8r)-3-Methoxybicyclo[3.2.1]oct-8-yl]carbonyl}-8-morpholin-4-yl-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepine,
6-{[(3s,8s)-3-methoxybicyclo[3.2.1]oct-8-yl]carbonyl}-8-morpholin-4-yl-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepine,
2-Methyl-2-[6-(6,7,8,9-tetrahydro-5H-benzo[7]annulen-7-ylcarbonyl)-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepin-8-yl]propanenitrile,
6-(spiro[2.5]oct-1-ylcarbonyl)-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepine,
6-(spiro[2.4]hept-1-ylcarbonyl)-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepine,
6-(bicyclo[1.1.1]pent-1-ylcarbonyl)-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepine,
6-[(3-phenylbicyclo[1.1.1]pent-1-yl)carbonyl]-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepine,
6-(bicyclo[3.1.1]hept-1-ylcarbonyl)-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepine,
6-(5,11-dihydro-6H-pyrido[2,3-b][1,5]benzodiazepin-6-ylcarbonyl)spiro[3.3]heptane-2-carboxylic acid,
8-morpholin-4-yl-6-(spiro[3.3]hept-2-ylcarbonyl)-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepine,
6-(2,3-dihydro-1H-inden-2-ylcarbonyl)-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepine,
6-(2,3-dihydro-1H-inden-1-ylcarbonyl)-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepine,
2-[6-(2,3-dihydro-1H-inden-2-ylcarbonyl)-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepin-8-yl]-2-methylpropanenitrile,
6-[(3aS,6aS)-octahydropentalen-1-ylcarbonyl]-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepine,
(1R,5S)-6-(5,11-dihydro-6H-pyrido[2,3-b][1,5]benzodiazepin-6-ylcarbonyl)bicyclo[3.2.1]octan-2-ol,
6-[(2S)-bicyclo[2.2.1]hept-2-ylcarbonyl]-6,11-dihydro-5H-pyrido[2,3-b][1.5]benzodiazepine,
6-(bicyclo[2.2.1]hept-1-ylcarbonyl)-8-morpholin-4-yl-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepine,
6-[(6,6-difluorobicyclo[3.1.0]hex-3-yl)carbonyl]-8-morpholin-4-yl-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepine,
6-{[(1R,3r,5S)-6,6-difluorobicyclo[3.1.0]hex-3-yl]carbonyl}-8-morpholin-4-yl-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepine,
8-morpholin-4-yl-6-[(3aR,6aR)-octahydropentalen-1-ylcarbonyl]-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepine,
6-(1,2,3,4-tetrahydronaphthalen-2-ylcarbonyl)-6,11-dihydro-5H-pyrido[2,3-b][1.5]benzodiazepine,
methyl 4-(5,11-dihydro-6H-pyrido[2,3-b][1,5]benzodiazepin-6-ylcarbonyl)bicyclo[2.2.2]octane-1-carboxylate,
6-[(2-methyl-1,2,3,4-tetrahydronaphthalen-2-yl)carbonyl]-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepine,
6-(bicyclo[2.2.2]oct-1-ylcarbonyl)-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepine,
6-[(3s,5s,7s)-tricyclo[3.3.1.1˜3.7˜]dec-1-ylcarbonyl]-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepine,
4-(5,11-dihydro-6H-pyrido[2,3-b][1,5]benzodiazepin-6-ylcarbonyl)bicyclo[2.2.2]oct-2-ene-1-carbonitrile,
1-[4-(5,11-dihydro-6H-pyrido[2,3-b][1,5]benzodiazepin-6-ylcarbonyl)bicyclo[2.2.2]oct-2-en-1-yl]ethanone,
6-[(4-pentylbicyclo[2.2.2]oct-1-yl)carbonyl]-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepine,
6-(bicyclo[3.1.1]hept-1-ylcarbonyl)-6,11-dihydro-5H-pyrido[2.3-b][1,5]benzodiazepine,
6-[(8,8-difluorobicyclo[3.2.1]oct-3-yl)carbonyl]-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepine,
6-[(3-fluorotricyclo[3.3.1.1˜3,7˜]dec-1-yl)carbonyl]-8-morpholin-4-yl-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepine,
6-[(3,5-difluorotricyclo[3.3.1.1˜3,7˜]dec-1-yl)carbonyl]-8-morpholin-4-yl-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepine,
8-Morpholin-4-yl-6-(1,2,3,4-tetrahydronaphthalen-2-ylcarbonyl)-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepine,
2-[6-(6,7,8,9-Tetrahydro-5H-benzo[7]annulen-7-ylcarbonyl)-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepin-8-yl]propan-2-ol,
2-Morpholin-4-yl-11-(6,7,8,9-tetrahydro-5H-benzo[7]annulen-7-ylcarbonyl)-10,11-dihydro-5H-dipyrido[2,3-b:2′,3′-e][1,4]diazepine,
4-[6-(6,7,8,9-Tetrahydro-5H-benzo[7]annulen-7-ylcarbonyl)-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepin-8-yl]pyrrolidin-2-one,
3-[6-(6,7,8,9-Tetrahydro-5H-benzo[7]annulen-7-ylcarbonyl)-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepin-8-yl]-1,3-oxazolidin-2-one,
4-Methyl-5-[6-(6,7,8,9-tetrahydro-5H-benzo[7]annulen-7-ylcarbonyl)-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepin-8-yl]-1,3-oxazolidin-2-one, and
(4R)-4-(1-Methylethyl)-3-[6-(6,7, 8,9-tetrahydro-5H-benzo[7]annulen-7-ylcarbonyl)-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepin-8-yl]-1,3-oxazolidin-2-one,
or a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 1)

A composition which comprises an inert carrier or excipient and a compound of claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 18

(canceled)

### Claim 19 (depends on 1)

A method for treating a disease or disorder associated with mutant IDH enzyme activity in a mammalian subject which comprises administering to the subject an effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 20

(canceled)

### Claim 21 (depends on 19)

The method of claim 19, wherein the disease or disorder associated with mutant IDH enzyme activity is a cancer selected from the group consisting of glioma, glioblastoma multiforme, paraganglioma, supratentorial primordial neuroectodermal tumors, acute myeloid leukemia (AML), breast cancer, prostate cancer, thyroid cancer, colon cancer, chondrosarcoma, cholangiocarcinoma, peripheral T-cell lymphoma, and melanoma.

### Claim 22 (depends on 21)

The method of claim 21, wherein the cancer is selected from glioma, glioblastoma multiforme, acute myeloid leukemia, and breat cancer.

### Claim 23

(canceled)
